Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $619

Benzinga · 2d ago
Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $595 to $619.